key: cord-0697957-2e6yid6i authors: Liu, Jia; Yan, Weiqi; Liu, Zhuojun; Han, Yizhao; Zhang, Leqiang; Yu, Jian title: A colloidal gold-based immunochromatographic strip for rapid detection of SARS-CoV-2 antibodies after vaccination date: 2021-06-26 journal: Med Nov Technol Devices DOI: 10.1016/j.medntd.2021.100084 sha: 2e7da717c518d8311195cf642a6deea721e15cff doc_id: 697957 cord_uid: 2e6yid6i Vaccination is an important device to block the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and effectively protect the organism from pathogen infection. However, a quick and accurate technique to evaluate the immune efficacy of the Novel Coronavirus inactivated vaccine remains scarce. In this paper, the IgM-IgG antibody combined detection colloidal gold immunochromatography assay kit was optimized and developed, which can detect the efficacy of the inactivated SARS-CoV-2 vaccine. We collected fingertip blood samples from 3 vaccinees and 1 unvaccinated person. The results showed that the proportion of antibody was high after the second dose immunization. The IgM-IgG combined antibody assay is rapid, convenient and easy to operate. It can be used as an auxiliary method for preliminary evaluation of the antibody effect of vaccine recipients, and provide a reference index for the potential clinical application value of the vaccine. conducted with the permission of both the subject and the unsubjects. 30 mmol /L sodium dihydrogen phosphate, 500 mmol /L sodium chloride, 10% 106 glycerol. Single colonies were isolated into a 5 mL LB test tube (50 μg /mL 107 Kanamicin) and cultured overnight at 37 ℃ at 220 r/min. According to zero. 5% 108 inoculation was transferred to 160 mL LB flask (50 μg /mL kanamycin), 3 vials each, 109 with an initial OD value of about 0. Cultured at 30 ℃ at 200 r/min for 3~4h to 0. Polyethylene fiberboard was selected as the supporting layer of colloidal gold test 132 strip, sample pad and release pad were prepared with glass fiber dimension, NC film 133 was selected to prepare the test layer, and absorbent paper was selected to prepare the concentrations of markers and coated reagents. NTD was used to test the detection 162 reagents, and the best combination was selected to determine the detection formula. 163 After the preparation of reagent test strips, all samples were tested according to the 164 test method and the test results were analyzed. 165 The blood sample to be tested and blood diluent were balanced to room 177 temperature, then the aluminum foil bag was unsealed. The test card was taken out According to the test results, the optimal labeled pH value of reagent strip was 217 determined to be 7.2. The optimal amount of antigen labeling was 0.5mg/100mL 218 colloidal gold solution. The best colloid gold working solution was 20mmol/L 219 phosphate buffer solution (BSA concentration was 2%, sucrose 10%, trehalose 5%, 220 0.01 mol/L Tris, pH 8.0). The optimal concentration of coated antigen was 2.0 mg 221 /mL, and the optimal determination time was 8 to 10min. The strip can be used for 222 qualitative screening of IgM-IgG antibody in the recipients of COVID-19 vaccine. 223 224 The positive detection rate of IgG in the samples was 100.00%, and that in the 226 samples with both IgM and IgG positive was 100.00% (Figure 3) . Whole blood 227 samples from randomly selected uninoculated individuals were tested for antibodies 228 and found to be negative. The sensitivity and specificity of the kit in this study were 229 100 % and 100% respectively. Article type ： All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated. Please state any sources of funding for your research: The journal requires that the corresponding author, signs on behalf of all authors, a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated. A conflicting interest exists when professional judgment concerning a primary interest (such as patient' s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies , stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no interests to declare then please state this: ' The authors declare that there are no conflicts of interest.' J o u r n a l P r e -p r o o f Please state any competing interests: The authors declare that there are no conflicts of interest If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly. All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) . The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study. The author should also clearly indicate in the Material and methods section of the manuscript that applicable guidelines, regulations and laws have been followed and required ethical approval has been obtained. Completion of this section is mandatory for Case Reports, Clinical Pictures, and Adverse Drug Reactions. Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to Medicine in Novel Technology and Devices. J o u r n a l P r e -p r o o f Pervasive generation of non-canonical subgenomic RNAs 272 by SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein SARS-CoV-2: Targeted managements and vaccine development mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19 Transmission and prevention of SARS-CoV-2 Detection and 284 infectivity potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) environmental 285 contamination in isolation units and quarantine facilities Characteristics of and Important Lessons From the Coronavirus Disease 288 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center 289 for Disease Control and Prevention Approaches and Challenges in SARS-CoV-2 Vaccine Development Current advances in the development of SARS-CoV-2 293 vaccines Randomized, double-blinded and 295 placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults Coronavirus vaccine development: from 298 SARS and MERS to COVID-19 Development of an inactivated vaccine 301 candidate for SARS-CoV-2 SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Immunogenicity of SARS 306 inactivated vaccine in BALB/c mice Immunogenicity, safety, and 309 protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys Severe acute respiratory 312 syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines Severe acute 315 respiratory syndrome coronavirus infection in vaccinated ferrets Enhanced protection in mice induced by 318 immunization with inactivated whole viruses compare to spike protein of middle east respiratory 319 syndrome coronavirus A systematic review of SARS-CoV-2 vaccine Current Status of COVID-19 323 (Pre)Clinical Vaccine Development To ensure clarity, you are required to enter the specific details of each author's contribution, which must substantiate the inclusion of each person on the manuscript. Roles for all authors should be described using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology Resources; Software; Supervision; Validation; Visualization Example: Elizabeth Ash: Conceptualization, Methodology, Software. Catriona Fennell: Data curation, Writing-Original draft preparation Weiqi Yan: Data curation：Writing-Reviewing and Editing